EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Protective Efficacy of a Modified Vaccinia Ankara-Based Vaccine Against Zika

Leidi Carvajal Aristizabal iD, Ivanna Hoyos Ramírez iD, Erwin Camacho iD, Daniel Maldonado, Esteban Marín, Juan Pablo Hernández-Ortiz iD, Jorge E Osorio

Vaccines · 10.03.2026 · 14 (3) · 252

DOI: 10.3390/vaccines14030252 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 10.03.2026. Verfasst von Leidi Carvajal Aristizabal und 6 weiteren Autor:innen. Beteiligte Einrichtung: VaxThera, Medellín 050031, Colombia. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia, Tecnología e Innovación, Ministerio de Ciencia, Tecnologia e Innovación.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Zika virus (ZIKV) is a mosquito-borne flavivirus associated with severe neurological disease, including congenital Zika syndrome (CZS) following utero infection and Guillain–Barré syndrome in adults. The 2015–2016 epidemic in the Americas highlighted the profound maternal and neonatal consequences of ZIKV infection. Although reported transmission has declined, ongoing circulation of competent vectors and population susceptibility sustain a substantial risk of future outbreaks, underscoring the need for effective vaccines.

Methods

We developed a recombinant Modified Vaccinia Ankara (MVA)-based vaccine candidate expressing the ZIKV pre-membrane (prM) and envelope (E) proteins and evaluated its immunogenicity and protective efficacy in interferon receptor-deficient AG129 mice.

Results

Vaccination induced strong humoral and cellular immune responses and conferred significant protection against viral replication in key target organs, including the brain and testes, following ZIKV challenge.

Conclusions

These preclinical findings support further development of this MVA-based ZIKV vaccine as a promising strategy to prevent ZIKV infection and its associated neurological complications.

Schlagwörter

Stichwörter der Autor:innen

Modified Vaccinia Ankara virusZika viruscell-mediated immunityflavivirusimmunitymiceneutralizing antibodiesvaccines

Autor:innen und Institutionen

  • VaxThera, Medellín 050031, Colombia.
  • One Health Genomic Laboratory, Department of Materials and Nanotechnology, Facultad de Minas, Universidad Nacional de Colombia, Sede Medellín, Medellín 050034, Colombia.
  • Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI 53706, USA.

ORCID-Profile: Leidi Carvajal Aristizabal, Ivanna Hoyos Ramírez, Erwin Camacho, Juan Pablo Hernández-Ortiz

Förderung

  • Ministerio de Ciencia, Tecnología e Innovación
  • Ministerio de Ciencia, Tecnologia e Innovación

Zitieren

APA

Carvajal Aristizabal, L., Hoyos Ramírez, I., Camacho, E., Maldonado, D., Marín, E., Hernández-Ortiz, J. P., & Osorio, J. E. (2026). Protective Efficacy of a Modified Vaccinia Ankara-Based Vaccine Against Zika. Vaccines, 14(3), 252. https://doi.org/10.3390/vaccines14030252

Vancouver

Carvajal Aristizabal L, Hoyos Ramírez I, Camacho E, Maldonado D, Marín E, Hernández-Ortiz JP, et al. Protective Efficacy of a Modified Vaccinia Ankara-Based Vaccine Against Zika. Vaccines. 2026;14(3):252. doi:10.3390/vaccines14030252

BibTeX
@article{CarvajalAristizabal2026,
  author = {Carvajal Aristizabal, Leidi and Hoyos Ramírez, Ivanna and Camacho, Erwin and Maldonado, Daniel and Marín, Esteban and Hernández-Ortiz, Juan Pablo and Osorio, Jorge E},
  title = {Protective Efficacy of a Modified Vaccinia Ankara-Based Vaccine Against Zika},
  journal = {Vaccines},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {252},
  doi = {10.3390/vaccines14030252}
}
Kostenlos starten →